Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy
Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prev...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ma, Wei-Cong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides - Nigolian, H. ELSEVIER, 2022, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:450 ; year:2013 ; number:1 ; day:25 ; month:06 ; pages:21-30 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijpharm.2013.04.023 |
|---|
| Katalog-ID: |
ELV021958939 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV021958939 | ||
| 003 | DE-627 | ||
| 005 | 20230625134536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2013.04.023 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013012000020.pica |
| 035 | |a (DE-627)ELV021958939 | ||
| 035 | |a (ELSEVIER)S0378-5173(13)00324-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.61 |2 bkl | ||
| 100 | 1 | |a Ma, Wei-Cong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. | ||
| 520 | |a Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. | ||
| 650 | 7 | |a Lipid emulsion |2 Elsevier | |
| 650 | 7 | |a Formulation optimization |2 Elsevier | |
| 650 | 7 | |a Asthma treatment |2 Elsevier | |
| 650 | 7 | |a α-Asarone |2 Elsevier | |
| 650 | 7 | |a Safety evaluation |2 Elsevier | |
| 700 | 1 | |a Zhang, Qing |4 oth | |
| 700 | 1 | |a Li, Hui |4 oth | |
| 700 | 1 | |a Larregieu, Caroline A. |4 oth | |
| 700 | 1 | |a Zhang, Na |4 oth | |
| 700 | 1 | |a Chu, Ting |4 oth | |
| 700 | 1 | |a Jin, Hui |4 oth | |
| 700 | 1 | |a Mao, Sheng-Jun |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Nigolian, H. ELSEVIER |t Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |d 2022 |g New York, NY [u.a.] |w (DE-627)ELV008932840 |
| 773 | 1 | 8 | |g volume:450 |g year:2013 |g number:1 |g day:25 |g month:06 |g pages:21-30 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijpharm.2013.04.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.61 |j Innere Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 450 |j 2013 |e 1 |b 25 |c 0625 |h 21-30 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
w c m wcm |
|---|---|
| matchkey_str |
maweicongzhangqinglihuilarregieucaroline:2013----:eeomnoitaeosiieusooaaoeihinfcnlipoes |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
44.61 |
| publishDate |
2013 |
| allfields |
10.1016/j.ijpharm.2013.04.023 doi GBVA2013012000020.pica (DE-627)ELV021958939 (ELSEVIER)S0378-5173(13)00324-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ma, Wei-Cong verfasserin aut Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Elsevier Zhang, Qing oth Li, Hui oth Larregieu, Caroline A. oth Zhang, Na oth Chu, Ting oth Jin, Hui oth Mao, Sheng-Jun oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 https://doi.org/10.1016/j.ijpharm.2013.04.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 450 2013 1 25 0625 21-30 10 045F 610 |
| spelling |
10.1016/j.ijpharm.2013.04.023 doi GBVA2013012000020.pica (DE-627)ELV021958939 (ELSEVIER)S0378-5173(13)00324-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ma, Wei-Cong verfasserin aut Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Elsevier Zhang, Qing oth Li, Hui oth Larregieu, Caroline A. oth Zhang, Na oth Chu, Ting oth Jin, Hui oth Mao, Sheng-Jun oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 https://doi.org/10.1016/j.ijpharm.2013.04.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 450 2013 1 25 0625 21-30 10 045F 610 |
| allfields_unstemmed |
10.1016/j.ijpharm.2013.04.023 doi GBVA2013012000020.pica (DE-627)ELV021958939 (ELSEVIER)S0378-5173(13)00324-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ma, Wei-Cong verfasserin aut Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Elsevier Zhang, Qing oth Li, Hui oth Larregieu, Caroline A. oth Zhang, Na oth Chu, Ting oth Jin, Hui oth Mao, Sheng-Jun oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 https://doi.org/10.1016/j.ijpharm.2013.04.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 450 2013 1 25 0625 21-30 10 045F 610 |
| allfieldsGer |
10.1016/j.ijpharm.2013.04.023 doi GBVA2013012000020.pica (DE-627)ELV021958939 (ELSEVIER)S0378-5173(13)00324-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ma, Wei-Cong verfasserin aut Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Elsevier Zhang, Qing oth Li, Hui oth Larregieu, Caroline A. oth Zhang, Na oth Chu, Ting oth Jin, Hui oth Mao, Sheng-Jun oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 https://doi.org/10.1016/j.ijpharm.2013.04.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 450 2013 1 25 0625 21-30 10 045F 610 |
| allfieldsSound |
10.1016/j.ijpharm.2013.04.023 doi GBVA2013012000020.pica (DE-627)ELV021958939 (ELSEVIER)S0378-5173(13)00324-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Ma, Wei-Cong verfasserin aut Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Elsevier Zhang, Qing oth Li, Hui oth Larregieu, Caroline A. oth Zhang, Na oth Chu, Ting oth Jin, Hui oth Mao, Sheng-Jun oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 https://doi.org/10.1016/j.ijpharm.2013.04.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 450 2013 1 25 0625 21-30 10 045F 610 |
| language |
English |
| source |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 |
| sourceStr |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:450 year:2013 number:1 day:25 month:06 pages:21-30 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Innere Medizin |
| institution |
findex.gbv.de |
| topic_facet |
Lipid emulsion Formulation optimization Asthma treatment α-Asarone Safety evaluation |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| authorswithroles_txt_mv |
Ma, Wei-Cong @@aut@@ Zhang, Qing @@oth@@ Li, Hui @@oth@@ Larregieu, Caroline A. @@oth@@ Zhang, Na @@oth@@ Chu, Ting @@oth@@ Jin, Hui @@oth@@ Mao, Sheng-Jun @@oth@@ |
| publishDateDaySort_date |
2013-01-25T00:00:00Z |
| hierarchy_top_id |
ELV008932840 |
| dewey-sort |
3610 |
| id |
ELV021958939 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021958939</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134536.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2013.04.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013012000020.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021958939</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(13)00324-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ma, Wei-Cong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipid emulsion</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Formulation optimization</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Asthma treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">α-Asarone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Safety evaluation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Qing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Hui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larregieu, Caroline A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Na</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chu, Ting</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jin, Hui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mao, Sheng-Jun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:450</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">day:25</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:21-30</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2013.04.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">450</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="b">25</subfield><subfield code="c">0625</subfield><subfield code="h">21-30</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ma, Wei-Cong |
| spellingShingle |
Ma, Wei-Cong ddc 610 bkl 44.61 Elsevier Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| authorStr |
Ma, Wei-Cong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008932840 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.61 bkl Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation Elsevier |
| topic |
ddc 610 bkl 44.61 Elsevier Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation |
| topic_unstemmed |
ddc 610 bkl 44.61 Elsevier Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation |
| topic_browse |
ddc 610 bkl 44.61 Elsevier Lipid emulsion Elsevier Formulation optimization Elsevier Asthma treatment Elsevier α-Asarone Elsevier Safety evaluation |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
q z qz h l hl c a l ca cal n z nz t c tc h j hj s j m sjm |
| hierarchy_parent_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| hierarchy_parent_id |
ELV008932840 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008932840 |
| title |
Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| ctrlnum |
(DE-627)ELV021958939 (ELSEVIER)S0378-5173(13)00324-4 |
| title_full |
Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| author_sort |
Ma, Wei-Cong |
| journal |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| journalStr |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
21 |
| author_browse |
Ma, Wei-Cong |
| container_volume |
450 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 44.61 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ma, Wei-Cong |
| doi_str_mv |
10.1016/j.ijpharm.2013.04.023 |
| dewey-full |
610 |
| title_sort |
development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| title_auth |
Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| abstract |
Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. |
| abstractGer |
Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. |
| abstract_unstemmed |
Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
1 |
| title_short |
Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy |
| url |
https://doi.org/10.1016/j.ijpharm.2013.04.023 |
| remote_bool |
true |
| author2 |
Zhang, Qing Li, Hui Larregieu, Caroline A. Zhang, Na Chu, Ting Jin, Hui Mao, Sheng-Jun |
| author2Str |
Zhang, Qing Li, Hui Larregieu, Caroline A. Zhang, Na Chu, Ting Jin, Hui Mao, Sheng-Jun |
| ppnlink |
ELV008932840 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ijpharm.2013.04.023 |
| up_date |
2024-07-06T20:51:09.122Z |
| _version_ |
1803864316703670272 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021958939</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134536.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2013.04.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013012000020.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021958939</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(13)00324-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ma, Wei-Cong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Severe adverse events have been frequently associated with taking the commercially available formulation of α-asarone injection (α-asarone-I). Hence, we sought to develop an intravenous lipid emulsion of α-asarone (α-asarone-LE), where we hypothesized that these adverse events could be prevented. Using a central composite design-response surface methodology, we developed and optimized an emulsion formulation of α-asarone-LE that composed of 10.0% (w/v) soybean oil, 0.4% (w/v) α-asarone, 1.2% (w/v) soybean lecithin, 0.3% (w/v) F68, and 2.2% (w/v) glycerol. The mean particle size of α-asarone-LE was 226±11nm, the ζ-potential was −25.6±1.2mV, the encapsulation efficiency was 99.2±0.1% and the drug loading efficiency was 3.45%. Stability, safety, and efficacy studies of α-asarone-LE were systematically investigated and compared to those of α-asarone-I. The α-asarone-LE not only showed a desired stability, but also exhibited excellent safety and improved efficacy in vivo, indicating its great potential for clinical application in the future.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipid emulsion</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Formulation optimization</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Asthma treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">α-Asarone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Safety evaluation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Qing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Hui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larregieu, Caroline A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Na</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chu, Ting</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jin, Hui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mao, Sheng-Jun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:450</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">day:25</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:21-30</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2013.04.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">450</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="b">25</subfield><subfield code="c">0625</subfield><subfield code="h">21-30</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4012136 |